Aysun AYBAL KUTLUGÜN, Esin BEYAN, Betül ERGÜN, Mustafa Çağrı ERGÜN, Galip AKTÜRK

Investigation of the effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on anemia in patients with normal or mildly low glomerular filtration rate

Background/aim: The relationship between the activation of the renin-angiotensin system and the increase in erythropoiesis has been shown in many studies. In addition, the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARB) has been reported to reduce hemoglobin levels in various patient groups at risk for secondary erythrocytosis/polycythemia. The aim of our study is to investigate whether there is a change in hemoglobin levels after starting ACEIs or ARBs in patients who have not used them before. Materials and methods: Three hundred and fifty-one patients who were started on renin angiotensin aldosterone system (RAAS) blockers were evaluated retrospectively. None of the patients had anemia before starting RAAS blockers. A median of 6 (4–12) months after the start of the drug, complete blood count and kidney function tests were evaluated. Hemoglobin values before and after the start of the drug were compared statistically. Results: A statistically significant decrease in mean Hb value was found after starting ACEIs or ARBs (14.39 ± 1.29 g/dL vs 13.98 ± 1.36 g/dL, p < 0.001). The decrease in control Hb values was higher in the ARB group than in the ACEI group (–0.53 ± 0.06 g/dL vs –0.29 ± 0.06 g/dL, p < 0.001). Conclusion: A significant decrease in mean Hb level was detected in the first year following the first administration of ACEIs or ARBs.Key words: Anemia, hypertension, renin, angiotensin, aldosterone

PDF

___

1. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M et al. The Cardioprotective Effects of the AngiotensinConverting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency. Insights From the EUROPA Trial. Journal of the American College of Cardiology 2007. doi:10.1016/j.jacc.2007.08.029
2. Marathias K, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos D. Hematocrit-lowering Effect Following Inactivation of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Current Topics in Medicinal Chemistry 2005. doi:10.2174/1568026043451311
3. Marusic-Vrsalovic M, Dominis M, Jaksic B, Kusec R. Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. British Journal of Haematology 2003. doi:10.1046/ j.1365-2141.2003.04598.x
4. Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G et al. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. American Journal of Medicine 1999. doi:10.1016/S0002-9343(98)00390-8
5. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. American Journal of Transplantation 2007. doi:10.1111/j.1600-6143.2007.01928.x
6. Plata R, Cornejo A, Arratia C, Anabaya A, Perna A et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: A prospective randomised trial. Lancet 2002. doi:10.1016/S0140-6736(02)07812-1
7. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. European Journal of Pharmacology 1998. doi:10.1016/S0014-2999(98)00451-8
8. Leshem-Rubinow E, Steinvil A, Zeltser D, Berliner S, Raz R et al. Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Mayo Clinic Proceedings 2012. doi:10.1016/j.mayocp.2012.07.020
9. Vlahakos DV, Balodimos C, Papachristopoulos V, Vassilakos P, Hinari E et al. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clinical Nephrology 1995.
10. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. Journal of Clinical Investigation 1997. doi:10.1172/JCI119769
11. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal of Kidney Diseases 1995. doi:10.1016/0272- 6386(95)90496-4
12. Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients [5]. Nephrology Dialysis Transplantation 1999. doi:10.1093/ndt/14.8.2047
13. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T et al. Pharmacoepidemiology of Anemia in Kidney Transplant Recipients. Journal of the American Society of Nephrology 2004. doi:10.1097/01.ASN.0000125551.59739.2E
14. Inoue A, Babazono T, Iwamoto Y. Effects of the reninangiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease. American Journal of Hypertension 2008. doi:10.1038/ajh.2007.53
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of Internal Medicine 2006. doi:10.7326/0003-4819-145-4-200608150-00004
16. Domenica Cappellini M, Motta I. Anemia in Clinical PracticeDefinition and Classification: Does Hemoglobin Change With Aging? Seminars in Hematology 2015. doi:10.1053/j. seminhematol.2015.07.006
17. Haznedaroglu IC, Tuncer S, Gursoy M. A local reninangiotensin system in the bone marrow. medical hypotheses 1996; 46: 507-510
18. Haznedaroglu IC, Beyazit Y. Local bone marrow reninangiotensin system in primitive, definitive and neoplastic haematopoiesis. Clinical Science 2013. doi:10.1042/ CS20120300
19. Strawn WB, Richmond RS, Tallant EA, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. British Journal of Haematology 2004. doi:10.1111/j.1365-2141.2004.04998.x
20. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney International 2001. doi:10.1046/j.1523- 1755.2001.00773.x
21. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrology Dialysis Transplantation 1998. doi:10.1093/ndt/13.5.1206
22. Pratt M, Lewis-Barned N, Walker R, Bailey R, Shand B et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. British Journal of Clinical Pharmacology 1992. doi:10.1111/j.1365-2125.1992.tb05644.x
23. Kamper AL, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation 1990. doi:10.3109/00365519009089178
24. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrology Dialysis Transplantation 1999. doi:10.1093/ndt/14.8.1836
25. Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines. Transplantation 1997. doi:10.1097/00007890-199709270-00021
26. Hirakata H, Onoyama K, Hori K, Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clinical Nephrology 1986.
27. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrology Dialysis Transplantation 2007. doi:10.1093/ndt/gfl716
28. Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: A systematic review and meta-analysis. QJM 2015. doi:10.1093/qjmed/hcv049